A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Trial Profile

A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs ADU-S100 (Primary) ; Ipilimumab
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Aduro BioTech
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 17 Apr 2018 According to an Aduro BioTech media release, Initial clinical data are expected in the second half 2018.
    • 01 Jun 2017 According to an Aduro BioTech media release, the company expects to expand this trial into viscerally accessible lesions in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top